IP
IndiaPulse

ZYDUSWELL

Large Cap

Zydus Wellness Limited

Consumer

Zydus Wellness Limited is an Indian consumer goods company focused on health and wellness products. It operates with 4 manufacturing facilities in India and 23 global 3P manufacturers, supported by a dedicated R&D Centre. The company reaches over 70 million families through 1,950+ distributors and 2.8 million stores, offering a portfolio aligned with global health and wellness trends.

₹508
-15.50 · -2.96%
Quote09 Jun, 10:02 am
Fundamentals09 Jun 2026 · screener
Score08 Jun, 11:00 pm · v4.2-nightly
Tags02 May 2026
Data confidence
Fresh enough for analysis
Investor decision lenses

One read, four checks

75+ is strong, 60-74 is usable, 45-59 is mixed, and below 45 needs caution. These are research lenses, not buy/sell instructions.

Weak fundamentals, management trust is acceptable, price trend is neutral, and recent execution is weak.

Suggested next step
Check latest quarters
Result consistency is weak; verify whether the thesis is improving or deteriorating.
U-Score
OVERVALUED
29

Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.

Trust
Mixed Trust
60

low confidence · 0/0 claims checked

Technical
Neutral
51

Timing lens: price trend and sector relative strength.

Result consistency
weak
29

Rolling lens: recent quarterly delivery, not the latest single-result score.

Latest result

Quarter ended 31 Mar 2026

Bad · 2/100

PAT -6% YoY · margin compression · Rev +63% YoY · +54% QoQ

Filed 18 May 2026
Open results browser →
MetricThis quarterYoYQoQ
Revenue₹1,485 Cr+62.6%+53.9%
EBITDA₹270 Cr+42.1%+342.6%
Operating margin18.0%-300 bps+1200 bps
PAT₹162 Cr-5.8%NDF
PAT margin10.9%-793 bps+1506 bps

NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.

Business and thesis

Where growth can come from, and what can break the case

Thesis under stressReviewed 2026-06-03T18:59:04.122Z
Management commentary snapshot

Q4 FY26 Net Sales surged 62.1% YoY, with FY26 Net Sales up 46.4% YoY, driven by acquisitions. Gross Contribution % expanded significantly. However, reported PAT declined -5.8% YoY in Q4 and -43.2% YoY for FY26, impacted by acquisition-related costs and exceptional items.

While top-line growth is robust, largely due to acquisitions, the significant decline in reported PAT raises concerns about the profitability and integration costs of these new businesses. Gross margin expansion is positive, but the mixed performance in domestic categories and ongoing geopolitical risks warrant close monitoring of adjusted profitability and organic growth drivers.

Current business mix

Geographic Mix for FY26

Latest issuer-disclosed distribution across 2 reported categories.

Businessmix
Domestic76.0%
International24.0%
Growth engines

Max Protein Portfolio Expansion

Maintains high momentum and leadership in protein snacking, entering four new categories and demonstrating ability to capitalize on trends.

Sugar Free Green Momentum

Continued strong momentum, delivering double-digit growth for the 20th consecutive quarter.

Everyuth Tan Removal Range

Delivered strong double-digit growth in FY26 and strengthened saliency with the Q4 FY26 launch of Tan Removal Face Wash.

International Business Growth

International business excluding Comfort Click delivered high double-digit topline growth despite geopolitical disruptions.

Tailwinds

Rural Demand Revival

Demand remains steady, supported by a strong revival in rural demand that continues to outpace urban recovery.

E-commerce & Quick Commerce Growth

Quick Commerce and E-commerce maintain strong growth momentum, contributing to distribution expansion.

Acquired Brands Contribution

Gross margin uplift further supported by the newly acquired brands.

Headwinds

Geopolitical Risks

Global geopolitical developments continue to create some pressure on costs and supply chains.

Divergent Commodity Pricing

Key commodities continue to show divergent pricing trends, impacting input costs.

Seasonal Headwinds

Performance of brands like Nycil and Glucon-D was impacted by softer category demand from adverse weather conditions in FY26.

Category Decline for Complan

The nutrition drink category declined by 4.8% vs last year, posing growth challenges for Complan.

Risk radar

Acquisition-Related Profitability Impact

Higher finance costs from acquisition funding and amortization of acquired brands led to lower reported PAT.

Competition and Economic Conditions

Forward-looking statements involve risks related to growth, competition, and domestic/international economic conditions affecting demand and prices.

Management accountability

What management said, and what results must prove

Issuer guidance and extracted claims are tracked against later reported outcomes. Treat these as management statements, not IndiaPulse forecasts.

Analyst reading lens
Compare BOTH

YoY comparison is essential for assessing annual performance and Q4 results in a seasonal business. QoQ trends are relevant for understanding sequential momentum in gross margins and the impact of fluctuating input costs.

Sector KPIs management disclosed

Gross Margin % to Net Sales

Q4 FY26: 64.8% (+1000 bps YoY); FY26: 60.2% (+772 bps YoY). Most brands recorded gross margin expansion, supported by newly acquired brands.

Rural Demand Trend

Strong revival in rural demand continues to outpace the gradual recovery in urban areas.

Organized Channel Saliency

Stood at 30% in FY26, comprising Modern Trade at 13% and E-commerce at 17%. Quick Commerce and E-commerce maintain strong growth momentum.

Market Share - Sugar Substitute

Sugar Free retained No. 1 position with 96.1% market share, supported by a 24 bps year-on-year gain (MAT Mar 2026).

Management forward view

Max Protein Category Expansion

Management believes Max Protein's ability to swiftly capitalize on emerging consumer trends contributes to category growth, market expansion, and long-term momentum.

Nycil Market Activation

Nycil is gearing up to strengthen brand communication and scale mass-market activations to enhance household penetration and retail reach.

Complan User Acquisition & Distribution

Management is focused on acquiring new users for Toddler & Adult nutrition portfolios through digital funnels, clinical credibility, expert outreach, and channel-led initiatives.

International Business Expansion

The company is leveraging global wellness opportunities through channel expansion (e.g., Boots.com) and geographical expansion (e.g., Amazon in UAE).

Thesis monitor

Numbers and claims to verify in the next filings

CheckpointCurrent evidenceWhat to verify next
Adjusted PAT GrowthQ4 FY26: +17.0% YoY; FY26: +2.3% YoYSustained growth in adjusted PAT, indicating successful integration and profitability of acquired businesses.
Gross Margin TrendQ4 FY26: 64.8%; FY26: 60.2%Continued expansion or stability, especially given volatile input costs and competitive pricing pressures.
Seasonal Brands PerformanceQ4 FY26: -9.8% YoY; FY26: -18.8% YoYRecovery in demand for seasonal brands like Glucon-D and Nycil, indicating effective mitigation of weather-related impacts.
International Business ContributionHigh double-digit topline growth (ex-Comfort Click)Continued expansion and increasing contribution to overall revenue and profitability, validating global market access strategy.

Verification checkpoints are IndiaPulse research interpretation, not investment advice.

Technical timing lens

Trend score and candlestick chart

51Neutral

SMA20 +18.6% / mo · near 52W low

Stock trend: 56
Sector RS: 45
Sector 3M: -0.7% vs Nifty +0.1%

Technical chart

ZYDUSWELLweekly · 1Y-73.4%
Latest close ₹509.25 on 2026-06-09
Bar
+1.2%
RSI
47
MACD hist
22.62
52W pos
6%
Hover for OHLC, volume, and indicators. Use range buttons above the chart to zoom.
₹255₹875₹1.5k₹2.1k₹2.7k52H52L2025-062025-092025-122026-03Vol2025-062025-102026-012026-052026-06
Up bar
Down bar
Volume
Result date
SMA 50
RSI(14)

Technical trend read

Bullish setup

Trend is constructive — long-term trend unclear. RSI 47.

  • SMA20 rising (~15.7% over last month) — short-term momentum positive.
  • RSI(14) at 47 — rising, no extreme reading.
  • MACD above signal but histogram contracting — bullish momentum cooling.
  • 81% off 52W high · 39% above 52W low.

Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.

Deep research

Valuation, score drivers, trust methodology, financials, and peers

Use these sections after reviewing the decision summary, latest result, thesis, management accountability, and technical timing above.

29U-SCORE
OVERVALUED

Fundamental score breakdown

OVERVALUED
Valuation4/30
Growth6/25
Quality0/20
Balance Sheet10/15
Cash Flow4/10
Piotroski
7/9 (+5)
Penalties
0
Raw sum
29

Why this score?

Top U-Score contributors and drags from the latest stored fundamentals.

29/100 · OVERVALUED

Positive drivers

  • Piotroski is strong at 7/9.
  • Balance sheet contributes 10/15 to the score.
  • Cash flow contributes 4/10 to the score.

Main drags

  • Fair-value margin of safety is negative at -1121.2%.
  • Quality is weaker at 0/20; verify the latest quarterly trend.
  • Valuation is weaker at 4/30; verify the latest quarterly trend.
Sector valuation model

Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks

Healthcare valuation needs both earnings quality and regulatory/pipeline context.

Pharma PE/EVEBITDA
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
69.8
PB
2.8
EV/EBITDA
29.5
ROE
4.0%
ROCE
5.0%
FCF Yield
Debt/Equity
0.6
MoS
-1121.2%
Score movement

Stored run vs live recompute

This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.

Stored run: 08 Jun 2026
v4.2-nightly
Final score
29
Previous: 28 (+1)
Verdict
OVERVALUED
Previous: OVERVALUED
Margin of safety
-1121.2%
Previous: -1162.2%

Score history

12 stored score snapshots. Latest stored move: -1 points.

08 Jun 2026
v4.2-nightly
29
29
29
29
29
29
29
29
29
29
29
28

Factor attribution

Penalties
0+1
was -1
Trust Score
60Mixed Trust · low confidenceTrust Lite

Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.

Mixed Trust: Claim history is still being built. It ranks around the 27th percentile of the scored universe and 26th percentile within Consumer. Main check: financial discipline is weak at 28/100.

Healthy Trust Lite: Promoter holding is 69.6%. Key concern: 2 latest quarters had PAT decline worse than 25% YoY.

Computed 08 Jun 2026
management-trust-v1
122 docs indexed · 64 concall links
Score band
Mixed Trust

Usable, but needs evidence. Treat guidance with a margin of safety.

Relative rank
27th percentile

overall median 67 · Consumer: 26th pctile, median 67 · Large: 16th pctile, median 74

Evidence depth
Financial-only

122 documents indexed, but claim history is not strong enough yet.

Claim delivery
Outcome history still building

0 claims extracted · No contradicted claim yet

How to read this Trust Score

Mixed Trust · low confidence
What it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Acceptable, but check the weakest sub-score before increasing exposure.

Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.

Forensic breakdown

Read low sub-scores as due-diligence warnings, not automatic sell signals.

Promoter
86
strong · holding, pledge, alignment
Cash flow
67
acceptable · profit to cash conversion
Balance sheet
81
strong · leverage and solvency
Discipline
28
weak · capital discipline
Results
29
weak · quarterly consistency

Trust positives

  • Promoter holding is 69.6%.
  • Promoter pledge is zero.
  • 10 years of positive FCF.
  • 4/4 latest quarters had positive YoY revenue growth.

Trust risks

  • 2 latest quarters had PAT decline worse than 25% YoY.
  • ROCE is low at 5%.
  • ROE is low at 4%.
  • Revenue CAGR is 21% but EPS CAGR is -10%.

Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.

Intrinsic value

Graham Number
₹159.78
-217.9% MoS
DCF Fair PE
6.7
DCF Fair Value
₹41.6
-1121.2% MoS
PEG

Fundamentals

Valuation

P/E
69.80
P/B
2.78
EV/EBITDA
29.53
Market Cap
16196.00Cr

Profitability

ROE
4.04%
ROCE
4.96%
ROA
1.91%
Dividend Y
0.24%

Growth (CAGR)

Revenue 5Y
16.00%
EPS 5Y
-2.00%
Revenue 3Y
21.00%
EPS 3Y
-10.00%

Balance Sheet

Debt/Equity
0.55
Interest Coverage
5.20×
Altman Z
3.70
Book Value
183.00

Cash Flow

FCF Yield
FCF Positive Y
10/5
OCF
226.00 Cr
EPS TTM
6.20

Shareholding

Promoter Hold
69.64%
Promoter Pledge
0.00%
Momentum 52W
78%

Financial History

Updated 9/6/2026

Revenue

₹ Cr
No data

Net Profit

₹ Cr
No data

Return on Equity

%
No data
Verify on:NSE India ↗
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.